A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease

Overview

About this study

The purpose of this study is to assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active Crohn's Disease (CD) in adult participants.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Biopsy-confirmed diagnosis of CD for at least 3 months prior to Baseline.

- Participant meets the following disease activity criteria:

1. Moderate to severe CD as assessed by COAi;

2. Endoscopic evidence of mucosal inflammation as documented by a SES-CD.

- Participant has demonstrated intolerance, loss of response or inadequate response to
conventional or advanced therapies for CD.

Exclusion Criteria:

- Participants with a current diagnosis of ulcerative colitis or indeterminate colitis.

- Participants with unstable doses of concomitant Crohn's disease therapy.

- Participants with prior exposure to p19 inhibitors.

- Participants with complications of Crohn's disease.

- Participants having an ostomy or ileoanal pouch.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/3/23. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus, M.D.

Contact us for the latest status

Contact information:

Shelly Ward

Ward.Shelly1@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20565822

Mayo Clinic Footer